此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

2026年10月1日 更新者:Fred Hutchinson Cancer Center

A Neoadjuvant Trial of Pasritamig in Unfavorable Intermediate to Very High-Risk Localized Prostate Cancer

This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer. Pasritamig is a bispecific antibody that works by bringing immune cells called T cells close to prostate cancer cells that express KLK2, which may help the immune system attack the cancer. Giving pasritamig before radical prostatectomy may help researchers determine how the drug affects prostate cancer and the immune cells within the tumor.

研究概览

地位

尚未招聘

条件

干预/治疗

研究类型

介入性

注册 (估计的)

18

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Washington
      • Seattle、Washington、美国、98109
        • Fred Hutch/University of Washington Cancer Consortium
        • 接触:
        • 首席研究员:
          • Steven Blinka, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Must be willing to provide informed consent prior to any study specific procedures.

  • Age ≥ 18 years.

  • Documented histologically confirmed adenocarcinoma of the prostate:

    • Unfavourable intermediate risk:

      --- Grade Group 1 with PSA 10-20 ng/mL, T2b-T2c OR Grade Group 2 with PSA 10-20 ng/mL, T2b-T2c, and/or ≥50% biopsy cores positive OR Grade Group 3 with PSA <20 ng/mL.

    • High-risk localized prostate cancer with no very-high-risk features and exactly one high-risk feature:

      • T3a OR
      • Grade Group 4 or 5 OR
      • PSA > 20 ng/dL
    • Very high-risk localized prostate cancer. At least one of the following:

      • T3b-T4
      • Primary Gleason pattern 5
      • 2 or 3 high-risk features
      • >4 cores with Grade Group 4 or 5
  • Negative for distant metastases on conventional (i.e. CT bone scan) and PSMA PET imaging within 60 days of enrollment. Patients with evidence of non-measurable (i.e. per RECIST v1.1) metastatic lymphadenopathy as detected by PSMA PET will be eligible if ≤3 radiation isocenters are detectable.

  • Eastern cooperative oncology group performance (ECOG) status 0-1.

  • Eligible and planned for radical prostatectomy.

  • Must have adequate archival biopsy tissue available for KLK2 assessment.

  • Participants who are sexually active with a partner of childbearing potential or a pregnant partner must agree to use contraception, including a condom, during study treatment and for at least 6 months after the last dose of pasritamig. Participants must also agree not to donate sperm during study treatment and for at least 6 months after the last dose of pasritamig.

  • Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • Hemoglobin ≥ 9 g/dL with no blood transfusion in the past 28 days

    • Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; however, participants with documented Duffy-null associated neutrophil count or other benign chronic neutropenia may be eligible with ANC ≥1.0 × 10⁹/L if clinically stable and without a history of recurrent or severe infections, at the discretion of the investigator. Platelet count ≥ 100 x 109/L

    • Total bilirubin ≤1.5 × institutional upper limit of normal (ULN), except participants with known or suspected Gilbert syndrome may be eligible with total bilirubin ≤3 × ULN, provided direct bilirubin is ≤1.5 × ULN and there is no clinical evidence of hepatic dysfunction.Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN

    • Patients must have creatinine clearance estimated of ≥30 mL/min:

      • Estimated creatinine clearance = (140-age [years]) x weight (kg) / serum creatinine (mg/dL) x 72

Exclusion Criteria:

  • Subjects with small cell or neuroendocrine prostate cancer.

  • Active infection or condition that requires treatment with systemic antibiotics within 7 days prior to the first dose of study treatment. Prophylactic anti-infective agents are allowed.

  • Solid organ or bone marrow transplantation.

  • Suspected or known allergies, hypersensitivity, or intolerance to excipients of pasritamig (refer to the latest IB for pasritamig).

  • Received immunosuppressive doses of systemic medications, such as glucocorticoids (doses >10 mg/day prednisone or equivalent) within 3 days prior to the first dose of study treatment. A single course of glucocorticoids is permitted as prophylaxis for imaging contrast (i.e., for participants with allergies to contrast). If glucocorticoids were used to treat immune-related adverse events associated with prior therapy, ≥7 days must have elapsed since the last dose of corticosteroid.

  • Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment. Live, attenuated influenza vaccines are permitted as late as 7 days before the study treatment.

  • Distant metastasis based on conventional imaging (clinical stage M1) and PSMA PET within 60 days of enrollment. Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Participants are considered eligible only if the central radiological review confirms clinical stage M0. As noted above, non-measurable nodal metastases detected on PSMA PET will be allowed to enroll if radiation isocenters are detectable.

  • cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles) is excluded.

  • Prior androgen deprivation therapy or other systemic treatment for prostate cancer.

  • Prior treatment with KLK2-targeted therapy and/or with any CD3-directed therapy

  • Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. This includes, but not limited to, the following:

    • Patients with positive HIV titers or active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
    • Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
    • Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
  • Any of the following within 6 months prior to first dose of study treatment:

    • Myocardial infarction,
    • Severe or unstable angina,
    • Clinically significant ventricular arrhythmias,
    • Congestive heart failure (New York Heart Association class II to IV),
    • Transient ischemic attack,
    • Cerebrovascular accident
  • Active autoimmune disease within the 12 months prior to signing consent that requires systemic immunosuppressive medications (e.g., chronic corticosteroid, methotrexate, or tacrolimus).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Neoadjuvant Pasritamig

Participants receive pasritamig IV on days 1, 8, 15, and 57. Participants then undergo standard of care radical prostatectomy. Participants also undergo blood and tissue sample collection on study.

Given IV

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility of neoadjuvant pasritamig
大体时间:From first dose through radical prostatectomy, approximately 70 days

Proportion of participants who complete planned neoadjuvant pasritamig and undergo radical prostatectomy within the protocol-defined surgical window without treatment-related delay.

From first dose through radical prostatectomy, approximately 70 days
Change in intratumoral CD3+ T-cell density
大体时间:Baseline to radical prostatectomy, approximately 70 days

Measured as CD3-positive T cells per mm² of evaluable tumor area

Baseline to radical prostatectomy, approximately 70 days

次要结果测量

结果测量
措施说明
大体时间
Adverse pathologic features
大体时间:At radical prostatectomy, approximately Day 70

Number and proportion of evaluable participants with extraprostatic extension (≥ypT3a), seminal vesicle invasion (ypT3b), regional lymph node involvement (ypN1), positive surgical margins, and any adverse pathologic feature.

At radical prostatectomy, approximately Day 70
Change in prostate-specific antigen (PSA)
大体时间:Screening through approximately 12 weeks following radical prostatectomy
Screening through approximately 12 weeks following radical prostatectomy
Time to biochemical recurrence or death
大体时间:From radical prostatectomy through up to 3 years of follow-up

Time from radical prostatectomy to biochemical recurrence or death, whichever occurs first. Biochemical recurrence is defined as postoperative PSA ≥0.2 ng/mL, confirmed by a second PSA ≥0.2 ng/mL when clinically feasible.

From radical prostatectomy through up to 3 years of follow-up
Pathologic complete response (pCR)
大体时间:At radical prostatectomy, approximately Day 70

Proportion of evaluable participants with no residual viable tumor identified on standard H&E evaluation of the radical prostatectomy specimen.

At radical prostatectomy, approximately Day 70
Pathologic downstaging
大体时间:At radical prostatectomy, approximately Day 70

Proportion of evaluable participants with a lower pathologic T stage at radical prostatectomy compared with baseline clinical T stage.

At radical prostatectomy, approximately Day 70
Proportion of participants with pathologic minimal residual disease (pMRD)
大体时间:At radical prostatectomy, approximately Day 70

Proportion of evaluable participants with residual viable carcinoma ≤5 mm in the greatest dimension of the largest residual tumor lesion and prostate-confined, lymph-node-negative disease (≤ypT2, ypN0).

At radical prostatectomy, approximately Day 70
Pathologic minimal residual disease (pMRD)
大体时间:At radical prostatectomy, approximately Day 70

pMRD is defined as residual viable carcinoma ≤5 mm in the greatest dimension of the largest residual tumor lesion with ≤ypT2 and ypN0 disease.

At radical prostatectomy, approximately Day 70
Residual cancer burden (RCB)
大体时间:At radical prostatectomy, approximately Day 70

RCB will also be quantified, with favorable RCB defined as ≤0.25 cm³ with ≤ypT2 and ypN0 disease.

At radical prostatectomy, approximately Day 70

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Steven Blinka, MD, PhD、Fred Hutchinson Cancer Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月30日

初级完成 (估计的)

2028年11月30日

研究完成 (估计的)

2028年11月30日

研究注册日期

首次提交

2026年10月1日

首先提交符合 QC 标准的

2026年10月1日

首次发布 (实际的)

2026年10月6日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅